Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fingolimod vs Standard DMT in RRMS (EPOC)
NCT01317004Phase 4Completed
- Sponsor
- Novartis
- Start
- May 2011
- Primary completion
- Jun 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of fingolimod in relapsing-remitting multiple sclerosis (RRMS), sponsored by Novartis. Started May 2011; status: completed.
02
Drugs
fingolimod
03
Conditions
relapsing-remitting multiple sclerosis (RRMS)
Beyond the preview
Go deeper on NCT01317004.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01317004.